Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Toby A. Eyre et al.|The Lancet|2021Cited by 456
Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Lindsey E. Roeker et al.|Blood|2020Cited by 318
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Lindsey E. Roeker et al.|Clinical Cancer Research|2020Cited by 115
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E. Roeker, Anthony R. Mato, Christopher P. Fox et al.|Clinical Cancer Research|2019Cited by 90
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignanciesRobert Stuver, Santosha A. Vardhana, Gunjan L. Shah et al.|Cancer Cell|2022Cited by 88